anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a readily administrable composition for oral administration, containing ibuprofen and a gastric-soluble high molecular compound and capable of masking unpleasant taste or mucosal irritancy. CONSTITUTION:The objective substance obtained by containing 1-90wt.% ibuprofen or a salt thereof and a gastric-soluble high molecular compound in an amount of 1-20 pts.wt. based on 100 pts.wt. ibuprofen and, as necessary, a disintegration agent (e.g. hydroxypropyl cellulose with a low substitution degree), adding a pharmaceutically acceptable excipient or carrier, etc., thereto, kneading and granulating the resultant mixture according to a conventional method and, as necessary, drying the pharmaceutical as a fine granule or granule. The ibuprofen with antipyretic and analgesic action has unpleasant taste and mucosal irritancy, which are masked by blending the gastric-soluble high molecular compound therewith without using a coating method. Polyvinyl acetal diethylaminoacetate is cited as the gastric-soluble high molecular compound.
APPEASED is a phase 1 open-label single arm pilot trial, aiming to determine the feasibility of a larger confirmatory randomized trial, and to characterize the prevalence of incomplete platelet inhibition after exposure to EC aspirin at doses of 80 mg once daily in patients with type 2 diabetes. The primary endpoint will be incomplete platelet aggregation in response to arachidonic acid at a concentration of 1mM, measured by LTA (Light Transmission Agregometry). For every platelet function assessment, serum salicylate concentration will also be measured. Upon the screening visit (day 0), blood will be drawn and baseline platelet function will be assessed. A 7 day supply of aspirin will be given to participants meeting the eligibility criteria. Participants will be instructed to take 1 dose of 80 mg of enteric coated aspirin per day at the same time every day. Upon day 7, participants will return for a second visit before the intake of their daily aspirin, and therefore 24 hours after the previous dose of aspirin was taken. Blood will be drawn and platelet function will be assessed in the same manner as described previously. Participants will then take their final dose of aspirin under supervision, and a final blood sample will be collected and platelet function will be assessed two hours later.
Patients receive dabrafenib PO BID on days 1-28 (once daily on day 1 and BID on days 3-28 of course 1), and pazopanib hydrochloride PO QD on days 1-28 (days 2-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Data collection tools were applied to individuals in the control group on day 0 (Z0), day 30 (Z1) and day 90 (Z2) of follow-up. Data collection tools applied to the control group are as follows: Patient Introduction Form, Heart Failure Symptom Status Scale, Minnesota Living with Heart Failure Questionnaire,Michel Uncertainty in Illness Scale - Community Form.
BACKGROUND: Ulcerative colitis (UC) is a chronic inflammatory disease of the colonic mucosa, with a gradually increasing incidence. Therefore, it is necessary to actively seek targets for the treatment of UC.
METHODS: Common differentially expressed genes (DEGs) were screened from two microarray data sets related to UC. Protein-protein interaction network was constructed to find the hub genes. The UC mouse model and cell model were induced by dextran sulfate sodium (DSS). The pathological changes of colon tissue were observed by hematoxylin-eosin staining. Immunohistochemistry and immunofluorescence were performed to detect the expressions of Ki67 and Claudin-1. The performance of mice was observed by disease activity index (DAI). The effect of TOP2A on proliferation, inflammation, oxidative stress, and interleukin-17 (IL-17) signaling pathway in UC model was measured by cell counting kit-8, enzyme-linked immunosorbent assay, and western blot.
RESULTS: Through bioinformatics analysis, 295 common DEGs were screened, and the hub gene TOP2A was selected. In UC model, there was obvious inflammatory cell infiltration in the colon and less goblet cells, while si-TOP2A lessened it. More Ki67 positive cells and less Claudin-1 positive cells were observed in UC model mice. Furthermore, knockdown of TOP2A increased the body weight and colon length of UC mice, while the DAI was decreased. Through in vivo and in vitro experiments, knockdown of TOP2A also inhibited inflammation and IL-17 signaling pathway, and promoted proliferation in DSS-induced NCM460 cells.
CONCLUSION: Knockdown of TOP2A alleviated the progression of UC by suppressing inflammation and inhibited IL-17 signaling pathway.
PURPOSE:To obtain an antibacterial molding having excellent antibacterial properties, antifungal properties and hygroscopicity and good shock absorption and being extensively used by mixing a polymer such as a urethane resin or a rubber with a fine fiber or powder of a hinokithiol-containing plant. CONSTITUTION:100 pts.wt. at least one polymer selected from among a urethane resin, a synthetic rubber and a natural rubber is mixed with 1-2000 pts.wt. fine fiber of a hinokithiol-containing plant and/or fine powder of a hinokithiol- containing plant. The obtained antibacterial molding has excellent antibacterial properties, antifungal properties and hygroscopicity, low resiliency and good shock absorption, can exhibit these effects sustainedly, excels in safety to the human body and can be mass-produced at low cost. It can be extensively applied for uses ranging from house wall and floor covering material to the inner sole of shoes.
It consists of 25 subjects with primary dysmenorrhea which were put on TENS for 30 minutes, three for 3 days. The subject were placed in supine lying in a comfortable position as possible. The abdomen to the inguinal region were decently exposed and cleaned, after inspection of the area for cuts, skin infections or any abnormalities. A pair of electrodes ( inactive electrodes) will be placed a little below the umbilicus ( Right and Left) and the other pair(active electrode) along the inguinal region at the level of pubic symphysis ( Right and Left) according to (Akinbo et al 2000). A quadripolar method will be used for electrode placement.
Prenatal cell-free DNA (cfDNA) screening uses extracellular fetal DNA circulating in the peripheral blood of pregnant women to detect prevalent fetal chromosomal anomalies. However, numerous severe conditions with underlying single-gene defects are not included in current prenatal cfDNA screening. In this prospective, multicenter and observational study, pregnant women at elevated risk for fetal genetic conditions were enrolled for a cfDNA screening test based on coordinative allele-aware target enrichment sequencing. This test encompasses the following three of the most frequent pathogenic genetic variations: aneuploidies, microdeletions and monogenic variants. The cfDNA screening results were compared to invasive prenatal or postnatal diagnostic test results for 1,090 qualified participants. The comprehensive cfDNA screening detected a genetic alteration in 135 pregnancies with 98.5% sensitivity and 99.3% specificity relative to standard diagnostics. Of 876 fetuses with suspected structural anomalies on ultrasound examination, comprehensive cfDNA screening identified 55 (56.1%) aneuploidies, 6 (6.1%) microdeletions and 37 (37.8%) single-gene pathogenic variants. The inclusion of targeted monogenic conditions alongside chromosomal aberrations led to a 60.7% increase (from 61 to 98) in the detection rate. Overall, these data provide preliminary evidence that a comprehensive cfDNA screening test can accurately identify fetal pathogenic variants at both the chromosome and single-gene levels in high-risk pregnancies through a noninvasive approach, which has the potential to improve prenatal evaluation of fetal risks for severe genetic conditions arising from heterogenous molecular etiologies. ClinicalTrials.gov registration: ChiCTR2100045739 .
PURPOSE:To obtain a carrier suited for serodiagnosis, etc. by contg. anionic or nonionic surfactants into a soln. contg. gelatin, water soluble polysaccharides, sodium polymetaphosphate as well as a hydrophilic org. solvent and water prior to adjusting of said soln. to a specific pH range. CONSTITUTION:Prior to adjusting of a soln. contg. gelatin, water soluble polysaccharides such as gum arabic, sodium polymetaphosphate (NaPO3)n, a hydrophilic org. solvent such as lower alcohol or aceton, and water to 2.5-6.0pH by adding acids under stirring at temp. higher than the gelling temp. of the gelatin, a soln. of anionic or nonionic surfactants is added thereto, then acids such as acetic acid soln. are added thereto to form gel particles. A particle dispersion is cooled and when the temp. thereof drops to <=10 deg.C, aldehyde crosslinking agents (glutaraldehyde, H2CO, etc.) are added to the soln. to obtain crosslinked gells. Thus, optional grain sizes can be provided to the carrier, and the homogeneous and stable carriers is obtained in good yields. The carrier bound with antigens or antibodies retains the initial characteristics without deterioration even when frozen abd preserved for a long period of time.
Group I received mandibular overdentures with a bar locator attachment , specially designed milled bar with parallel walls was built for this group, and two holes were drilled in the top surface of the bar using a 1.7 mm bar drill to create the threaded site in the waxed bar, followed by a 2.0 mm bar tap. The locator female component was then connected to the corresponding site using a customised rider.
The global burden of neurological disorders is evident, yet there remains limited efficacious therapeutics for their treatment. There is a growing recognition of the role of inflammation in diseases of the central nervous system (CNS); among the numerous inflammatory mediators involved, prostaglandins play a crucial role. Prostaglandins are small lipid mediators derived from arachidonic acid via multi-enzymatic pathways. The actions of prostaglandins are varied, with each prostaglandin having a specific role in maintaining homeostasis. In the CNS, prostaglandins can have neuroprotective or neurotoxic properties depending on their specific G-protein receptor. These G-protein receptors have varying subfamilies, tissue distribution, and signal transduction cascades. Further studies into the impact of prostaglandins in CNS-based diseases may contribute to the clarification of their actions, hopefully leading to the development of efficacious therapeutic strategies. This review focuses on the roles played by prostaglandins in neural degeneration, with a focus on Alzheimer's Disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis in both preclinical and clinical settings. We further discuss current prostaglandin-related agonists and antagonists concerning suggestions for their use as future therapeutics.
PURPOSE:To remarkably improve the solubility of adipic acid useful as an antiseptic agent for food, pharmaceutical, etc., by adding an alkali metal or alkaline earth metal phosphate to an aqueous system containing adipic acid. CONSTITUTION:An aqueous system containing adipic acid is prepared beforehand. Since adipic acid has low solubility in water, it is precipitated in the form of powder. The aqueous system is added with one or more kinds of alkali metal phosphate and/or alkaline earth metal phosphate (e.g. sodium phosphate, carbonate, etc.). The amount of the additive is >=1mol per 1mol of adipic acid. The precipitated adipic acid is converted to a state of molecular dispersion by this treatment to increase the solubility and improved the antiseptic effect to food, etc. In the case of treating a water-containing or aqueous food or pharmaceutical, adipic acid and the above phosphate may be directly added to the food without using an aqueous system.
NEW MATERIAL:A monoclonal antibody produced by a hybridoma prepared by using flat epithelial cancer derived strain (PC-10) of lung.middle degree differentiation type as an immune source having the following characteristics. Ig Class (subclass): IgM (K). Recognition antigen type: cell membrane superficial type antigen. Reactivity with cancerous cells; showing positive reactivity with lung cancer (PC-10) cell. USE:A diganosticum for flat epithelial cancer of lung.middle degree differentiation type, imaging for tumor and an antitumor agent. PREPARATION:For example, lung cancer cell (PC-10) is ground and extracted to give a high polymer fraction. A mouse, etc., is immunized against the fraction, a splenocyte is collected and subjected to cell fusion with myeloma cell to give a hybridoma. Then, it is cloned by limiting dilution to give a monoclone, which is transplanted into a mouse abdominal cavity and cultivated to give a monoclonal antibody.
Patients randomized to control group will go to a 2 months elimination diet (rice and turkey's meat). After 2 months of elimination diet they will crossover to a 2 months elimination diet (wheat and cow's milk products). After 2 months of elimination diet they will go to an open challenge, with reintroduction of wheat. After 2 weeks of open diet or whenever rheumatologic, intestinal and/or extraintestinal symptoms should return or intensify, patients will end the study.
Human induced pluripotent stem cells (hiPSC) and atrial hiPSC-derived cardiomyocytes (hiPSC-CM) have entered the arena of preclinical atrial fibrillation research. A central question is whether they reproduce the physiologic contribution of atrial selective potassium currents (such as the ultrarapid potassium current, I Kur ) to repolarization. Of note, 2 studies in single atrial hiPSC-CM reported prolongation of action potential duration by I Kur block indicating that I Kur might in fact represent a valuable target for the treatment of human atrial fibrillation. However, the results and interpretation are at odds with the literature on I Kur block in human atria and the results of clinical studies. We believe that the discrepancies indicate that experiments in single atrial CM (both adult atrial CM and atrial hiPSC-CM) might be misleading. Under particular experimental conditions, atrial hiPSC-CMs may not closely resemble the electrophysiology of the human atrium. Therefore, we recapitulate here methodological issues evaluating potential value of the I Kur as an antiarrhythmic target when investigated in animal models, in human atrial tissues, and finally in atrial hiPSC-CM.
This study aimed to develop a machine learning (ML)-based tool for early and accurate prediction of in-hospital mortality risk in patients with spontaneous intracerebral hemorrhage (sICH) in the intensive care unit (ICU). We did a retrospective study in our study and identified cases of sICH from the MIMIC IV (n = 1486) and Zhejiang Hospital databases (n = 110). The model was constructed using features selected through LASSO regression. Among five well-known models, the selection of the best model was based on the area under the curve (AUC) in the validation cohort. We further analyzed calibration and decision curves to assess prediction results and visualized the impact of each variable on the model through SHapley Additive exPlanations. To facilitate accessibility, we also created a visual online calculation page for the model. The XGBoost exhibited high accuracy in both internal validation (AUC = 0.907) and external validation (AUC = 0.787) sets. Calibration curve and decision curve analyses showed that the model had no significant bias as well as being useful for supporting clinical decisions. XGBoost is an effective algorithm for predicting in-hospital mortality in patients with sICH, indicating its potential significance in the development of early warning systems.
Patients in this group will receive Maitland mobilizations along with hot pack and TENS for pain and disability. A total of 3 sessions would be conducted over a period of 1 week.
Participants will be asked to follow TRE for 16 weeks with a protocol that is personalized to their preferences within the following pre-specified rules: 1) 8-10 hour eating window; 2) self-selected eating window start time as long as it ends ≥3h before bedtime; 3) if days off are required, aim to do so after following TRE for ≥5 successive days each week. Each participant will be matched with another participant in the same group to provide peer-based support to adhere to TRE. Study staff will introduce pairs and provide an introduction to TRE and then pairs will meet by phone/video at weeks 1, 3, 6, and 12 at a minimum, with additional contact encouraged.
BACKGROUND: Congenital muscular dystrophies (CMDs) are diverse early-onset conditions affecting skeletal muscle and connective tissue. This group includes collagen VI-related dystrophies such as Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM), caused by mutations in the COL6A1, COL6A2 and COL6A3 genes. We report a consanguineous Malian family with three siblings affected by UCMD due to a novel homozygous splice site variant in the COL6A1 gene.
METHODS: After obtaining consent, three affected siblings and their relatives underwent physical examinations by specialists and laboratory tests where possible. DNA was extracted from peripheral blood for genetic testing, including Whole Exome Sequencing (WES). Putative variants were confirmed through Sanger Sequencing and assessed for pathogenicity using in silico tools.
RESULTS: The three siblings and their healthy parents, from a consanguineous marriage, presented with early-onset progressive muscle weakness, walking difficulty, proximal motor deficits, severe muscle atrophy, hypotonia, skeletal deformities, joint hyperlaxity, ankyloses at the elbows and knees, keloid scars and dental crowding. No cardiac involvement was detected and creatine kinase (CK) levels were normal. All had low serum calcium levels, treated with oral supplements. Needle myography indicated myopathic patterns. WES identified a novel splice site variant in the first intron of COL6A1 (c.98-1G>C), which segregated with the disease within the family. This variant is predicted to cause exon 2 skipping in COL6A1, with a high CADD score of 33 and Splice AI predicting it as deleterious.
CONCLUSION: We identified a novel COL6A1 variant in a consanguineous family, highlighting the need for further studies in larger African cohorts to enhance genetic epidemiology and prepare for future therapeutic research.
Sorghum is considered to be an allelopathic crop species, producing phytotoxins such as the lipid benzoquinone sorgoleone (2-hydroxy-5-methoxy-3-[(Z,Z)-8′,11′,14′-pentadecatriene]-p-benzoquinone) which likely accounts for much of its allelopathic properties. Prior investigations into the biosynthesis of sorgoleone have suggested the participation of one or more alkylresorcinol synthases (ARS), which are type III polyketide synthases (PKS) that produce 5-alkylresorcinols using medium to long-chain fatty acyl-CoA starter units via iterative condensations with malonyl-CoA. Current evidence suggests that sorgoleone biosynthesis occurs exclusively in root hair cells, involving the synthesis of a 5-pentadecatrienyl resorcinol intermediate derived from an unusual 16:3 fatty acyl-CoA starter unit. To characterize the enzymes responsible for the biosynthesis of this alkylresorcinol intermediate, a previously-described expressed sequence tag (EST) database prepared from isolated root hairs was first mined for all PKS-like sequences. Quantitative real-time RT-PCR analyses revealed that two of these sequences were preferentially expressed in root hairs, and recombinant enzyme studies demonstrated that both sequences (designated ARS1 and ARS2) encode ARS enzymes capable of accepting a variety of fatty acyl-CoA starter units. Furthermore, RNA interference (RNAi) experiments directed against ARS1 and ARS2 resulted in the generation of multiple independent transformant events exhibiting dramatically reduced sorgoleone levels. Thus, both ARS1 and ARS2 are likely to participate in the biosynthesis of sorgoleone in planta. The sequences of ARS1 and ARS2 were also used to identify several rice genes encoding ARSs, which are likely involved in the production of defense-related alkylresorcinols.
PROBLEM TO BE SOLVED: To efficiently transfer data in the desired area of an image. SOLUTION: Original image data S0 provided by performing photographing while using a radiation field stop are hierarchized, and an image file F is composed of respective hierarchical data. The side channel of respective hierarchical data contains area information expressing the radiation field area. When transferring the image file F, the area information is received and a judging means 10 judges the importance degree of the area in the image. The judged result is inputted to a control means 8 and it is inputted to an image server 15 to perform transfer up to the hierarchical data of peak resolution concerning the important area but not to transfer any data concerning the unimportant area.  A transfer means 13 of the image server 15 receives this information, reads the image file F out of a storage device 6 and transfers the hierarchical data of peak resolution concerning the important area to a terminal 17.
Myocardial hypertrophy is the most common condition that accompanies heart development in children. Transcriptional gene expression regulating pathways play a critical role both in cardiac embryogenesis and in the pathogenesis of congenital hypertrophic cardiomyopathy, neonatal posthypoxic myocardial hypertrophy, and congenital heart diseases. This paper describes the state of cardiac gene expression and potential pharmacological modulators at different transcriptional levels. An experimental model of perinatal cardiac hypoxia showed the downregulated expression of genes responsible for cardiac muscle integrity and overexpressed genes associated with energy metabolism and apoptosis, which may provide a basis for a therapeutic approach. Current evidence suggests that RNA drugs, theaflavin, neuraminidase, proton pumps, and histone deacetylase inhibitors are promising pharmacological agents in progressive cardiac hypertrophy. The different points of application of the above drugs make combined use possible, potentiating the effects of inhibition in specific signaling pathways. The special role of N-acetyl cysteine in both the inhibition of several signaling pathways and the reduction of oxidative stress was emphasized.
The present invention relates to compositions suitable for external application to the skin, oral mucosa and scalp. In particular, the present invention relates to compositions having polymers for enhancing immunity. It is desirable to increase the natural defenses of the human body against infections by using naturally occurring compounds or ingredients, particularly as part of common cosmetic or dermatological preparations, since consumers often do not wish to rely solely on drugs. It is therefore an object of the present invention to provide a topical composition, in particular an oral, skin or hair composition, which provides enhanced immunity benefits. It is yet another object of the present invention to provide a method for producing an extract of camellia sinensis which provides enhanced immune benefits. The present inventors have determined that topical compositions having galacturonic acid polymers with a molecular weight of 18kD to 35kD provide enhanced immune benefits.